{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"94","value":"81.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \\< 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \\< 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.\n\nbortezomib\n\nthalidomide","id":"OG000","title":"Bortezomib and Thalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1-6 months","title":"Clinical Response to Treatment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}